Insights from investigating the interaction of oseltamivir (Tamiflu) with neuraminidase of the 2009 H1N1 swine flu virus.

@article{Wang2009InsightsFI,
  title={Insights from investigating the interaction of oseltamivir (Tamiflu) with neuraminidase of the 2009 H1N1 swine flu virus.},
  author={Shu-Qing Wang and Qi-Shi Du and Ri-Bo Huang and Dawei Zhang and Kuo-Chen Chou},
  journal={Biochemical and biophysical research communications},
  year={2009},
  volume={386 3},
  pages={
          432-6
        }
}
The neuraminidase (NA) of influenza virus is the target of anti-flu drugs oseltamivir and zanamivir. Clinical practices showed that oseltamivir was effective to treat the 2009-H1N1 influenza but failed to the 2006-H5N1 avian influenza. To perform an in-depth analysis on such a drug-resistance problem, the 2009-H1N1-NA structure was developed. To compare it with the crystal 2006-H5N1-NA structure as well as the 1918 influenza virus H1N1-NA structure, the multiple sequential and structural… Expand
SUSCEPTIBILITY OF COMMERCIAL NEURAMINIDASE INHIBITORS AGAINST 2013 A/H7N9 INFLUENZA VIRUS: A DOCKING AND MOLECULAR DYNAMICS STUDY
The latest influenza A (H7N9) virus attracted a worldwide attention due to the first report of human infections and the continuing reported cases in China. In this work, homology modeling, dockingExpand
Design, in silico studies, synthesis and in vitro evaluation of oseltamivir derivatives as inhibitors of neuraminidase from influenza A virus H1N1.
TLDR
Two compounds were selected for synthesis, which together with their respective intermediates were evaluated for their cytotoxicity and antiviral activities, and it was found that the compounds produced inhibitory activity on this enzyme. Expand
In silico modification of oseltamivir as neuraminidase inhibitor of influenza A virus subtype H1N1
TLDR
The results showed that AD3BF2D ligand can be used as a good candidate for neuraminidase inhibitor to cope with influenza A virus subtype H1N1. Expand
Activity of Isatine-Sulfadimidine Derivatives against 2009 Pandemic H1N1 Influenza Virus in Cell Culture
TLDR
SP III-5Br and SPIII-5H exhibited potency in the same range as ribavirin and are suitable candidate molecules for further investigation. Expand
Short communication Activity of isatine-sulfadimidine derivatives against 2009 pandemic H1N1 influenza virus in cell culture
TLDR
SP III-5Br and SPIII-5H exhibited potency in the same range as ribavirin and are suitable candidate molecules for further investigation. Expand
INFLUENZA A (H1N1) AND THE RESISTANCE TO OSELTAMIVIR
TLDR
This study was performed with the intention of collecting and compiling data about the occurrence of resistance to this medication, in particular due to a H274Y substitution, and about the association of the appearance of resistance with the use of the drug. Expand
Insights from investigating the interactions of adamantane-based drugs with the M2 proton channel from the H1N1 swine virus.
TLDR
The three-dimensional structure of the H1N1-M2 channel was developed based on the primary sequence taken from a patient recently infected by the H 1N1 (swine flu) virus, and it was found that their binding affinity is significantly lower than that to the H5N 1-M1 channel, fully consistent with the recent report that the H2N1 swine virus was resistant to the two drugs. Expand
Computational analysis and modeling the effectiveness of 'Zanamivir' targeting neuraminidase protein in pandemic H1N1 strains.
  • S. Gupta, Shishir K Gupta, +6 authors J. Vera
  • Biology, Medicine
  • Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases
  • 2011
TLDR
An ordinary differential equations based mathematical model for H1N1 infection dynamics and drug mediated virus deactivation is derived and it is suggested that there are considerable changes in the binding affinity of neuraminidase with zanamivir, which leads to probable ineffectiveness of zanAMivir in the isolated samples of pandemic H1n1 collected from quite a few countries. Expand
SCREENING OF H275Y MUTATION IN INFLUENZA A (H1N1) pdm09 ISOLATED IN MALAYSIA BY RAPID REAL-TIME PCR ASSAYS
TLDR
All 120 influenza A(H1N1) pdm09 Malaysian viral isolates collected during the 2009-2010 pandemic season were tested for the presence of H275Y mutation by Taqman Dual Probe Real-Time PCR and High Resolution Melting (HRM) assays, and the developed HRM assay was found to be robust and cheaper than sequencing andTaqman assay. Expand
In silico design of cyclic peptides as influenza virus, a subtype H1N1 neuraminidase inhibitor
TLDR
Based on molecular docking, new antiviral drug designs have been found that showed better activity and affinity than standard ligand to inhibit neuraminidase activity and DNY, NNY and LRL ligands have low toxicity and were predicted to have at least 59% possibility of being synthesized in wet laboratory experiment. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 73 REFERENCES
Study of drug resistance of chicken influenza A virus (H5N1) from homology-modeled 3D structures of neuraminidases.
TLDR
The structure-activity relationship between NA (neuraminidase) and its three inhibitors (DANA, zanamivir, and oseltamivIR) was investigated and it was indicated that 11 functional residues were highly conserved except for AAF02313 with the mutated virus strain. Expand
The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design
TLDR
It may be possible to exploit the size and location of the group-1 cavity to develop new anti-influenza drugs, according to X-ray crystallography, which shows that these two groups of neuraminidases are structurally distinct. Expand
Analogue inhibitors by modifying oseltamivir based on the crystal neuraminidase structure for treating drug-resistant H5N1 virus.
TLDR
It is revealed through the structure that the active sites of the group-1 neuraminidases, which contain the N1 subtype, have a very different three-dimensional structure from those of group-2 neuraminidsases. Expand
Computational studies of H5N1 influenza virus resistance to oseltamivir
TLDR
Detailed analyses indicated that conformational change of E276 in the Pocket 1 region of NA is a key source of drug resistance in the H274Y mutant but not in the N294S mutant. Expand
Insights from modeling the 3D structure of H5N1 influenza virus neuraminidase and its binding interactions with ligands.
TLDR
In insights into the secret why some of H5N1 strains bear high resistance for existing NA inhibitors, and stimulate new strategies for designing new drugs against these viruses, this investigation investigated the structure-activity relationship between NA (neuraminidase) and three inhibitors. Expand
Structural Characterization of the 1918 Influenza Virus H1N1 Neuraminidase
TLDR
These high-resolution structures from the 1918 “Spanish flu” and that of its complex with zanamivir (Relenza) at 1.65-Å and 1.45-A⩽ resolutions corroborated the successful expression of correctly folded NA tetramers in a baculovirus expression system. Expand
Neuraminidase Inhibitor-Resistant Recombinant A/Vietnam/1203/04 (H5N1) Influenza Viruses Retain Their Replication Efficiency and Pathogenicity In Vitro and In Vivo
TLDR
The results suggest that NA inhibitor-resistant H5N1 variants may retain the high pathogenicity of the wild-type virus in mammalian species and patients receiving NA inhibitors for H1N1 influenza virus infection should be closely monitored for the emergence of resistant variants. Expand
Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants
TLDR
The enzymatic properties and crystal structures of neuraminidase mutants from H5N1-infected patients are reported that explain the molecular basis of resistance and indicate that it would be prudent for pandemic stockpiles of oseltamivir to be augmented by additional antiviral drugs, including zanamivIR. Expand
Oseltamivir resistance during treatment of influenza A (H5N1) infection.
TLDR
It is suggested that resistance can emerge during the currently recommended regimen of oseltamivir therapy and may be associated with clinical deterioration and that the strategy for the treatment of influenza A (H5N1) virus infection should include additional antiviral agents. Expand
Zanamivir: a review of its use in influenza.
UNLABELLED Zanamivir is a novel inhibitor of the enzyme neuraminidase, a surface glycoprotein essential for the replication of type A and B influenza viruses. Statistically significant reductions inExpand
...
1
2
3
4
5
...